S.Biomedics’ stem cell therapy for Parkinson’s disease has shown positive results in an assessment of one-year data from the three patients (first low-dose cohort) in a Phase I/IIa clinical trial, raising expectations for findings from the high-dose group set to be announced later this year.
If these turn out to be positive, they could position the South Korean firm well in the expanded field of cell therapy for